PEDIATRICS Vol. 46 No. 4 October 1970, pp. 508-512
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Newcombe, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Newcombe, D. S.

THE URINARY EXCRETION OF AMINOIMIDAZOLECARBOXAMIDE IN THE LESCH-NYHAN SYNDROME

David S. Newcombe M.D., C.M.1

1 Department of Medicine, The University of Vermont, College of Medicine, Burlington, Vermont

The urinary excretion of aminoimidazolecarboxamide (AIC), an intermediate in purine synthesis, was studied in five patients with the Lesch-Nyhan syndrome. The mean urinary AIC level for these subjects was 12.03 ± 6.9 mg AIC/mg creatinine as compared to a mean urinary excretion in normal subjects of 1.2 ± 0.6 mg AIC/mg creatinine. None of the patients had clinical evidence of megaloblastic anemia at the time of the study, and their serum folate levels were within the normal range. The increased urinary AIC excretion probably represents a reflection of the deranged purine metabolism in this syndrome and its measurement can be used as a screen for the Lesch-Nyhan syndrome and other disorders of purine and/or folate metabolism.

Submitted on February 2, 1970
Accepted on April 2, 1970